

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 20, 2018

STRATA  
SKIN SCIENCES

STRATA SKIN SCIENCES, INC.  
(Exact Name of Registrant Specified in Charter)

Delaware  
(State or Other  
Jurisdiction of  
Incorporation)

000-51481  
(Commission File  
Number)

13-3986004  
(I.R.S. Employer  
Identification No.)

100 Lakeside Drive, Suite 100, Horsham, Pennsylvania 19044  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

## **Item 7.01 Regulation FD Disclosure**

On August 20, 2018 the Company issued a press release announcing that it had entered into a strategic marketing agreement with one of the nations' largest private equity backed dermatology groups, which allows STRATA to engage their individual offices to place the XTRAC<sup>®</sup> excimer laser utilizing STRATA's XTRAC business model of placement on a pay per use basis with no upfront cost to the practices.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed subject to the requirements of amended Item 10 of Regulation S-K, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

## **Safe Harbor Statement**

Statements in this report that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, the Company's continuing efforts to implement changes to our business with the goal of enhancing our strategic position in the medical and aesthetic dermatology market; ability to achieve growth in recurring revenues and other business sectors, ability to achieve and sustain a successful direct to customer marketing strategy and execution of that strategy, and the Company's ability to close on the referenced perpetual license agreement, or to monetize any remaining MelaFind assets are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results expressed or implied by such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this report as a result of new information, future events or otherwise.

## **Item 9.01 Financial Statements and Exhibits**

(d) Exhibits.

99.1

Strata Skin Sciences Press Release Dated August 20, 2018

| <u>Exhibit No.</u> | <u>Exhibit Description</u>   |
|--------------------|--|
| 99.1               | <a href="#">August 20, 2018 STRATA Skin Sciences, Inc. Press Release</a> |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**STRATA SKIN SCIENCES, INC.**

Date: August 22, 2018

By: /s/ Matthew C. Hill  
Matthew C. Hill  
Chief Financial Officer

## **STRATA Skin Sciences Announces Strategic Agreement with a Large Private Equity Backed Group of Dermatology Clinics**

*Agreement will add to group's business offering and enhance the individual clinics' abilities to offer proven and cost-effective treatments to psoriasis, vitiligo and atopic dermatitis patients*

**Horsham, PA, August 20, 2018** — (NASDAQ: SSKN) STRATA Skin Sciences, Inc. ("STRATA") a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the signing of a strategic marketing agreement with one of the nations' largest private equity backed dermatology groups.

The agreement allows for deployment across the group's network of dozens of clinics to place the XTRAC<sup>®</sup> excimer laser and to utilize STRATA's unique XTRAC value-add business model. The placement is on a pay per use basis with no upfront cost to the practices. STRATA provides clinical training, drives XTRAC utilization with direct to consumer (DTC) advertisement, and supports patients with advocacy.

The agreement will be implemented across the group's network, with the first 10 clinics expected to be deployed before the end of 2018.

Dr. Dolev Rafaeli, President and Chief Executive Officer of STRATA, commented, "We are pleased to announce this strategic relationship, which we believe will have significant benefits for both STRATA and the dermatology practice group. STRATA's unique business model offers physician practices unequalled business opportunities, while providing best in class technology to their patients. STRATA's field service team supports our partner physicians with unparalleled device up time. As part of our Physician Partner program, our clinical support team trains the physician's clinical staff, as well as subsequent hires, in the proper use of the XTRAC. In addition, we currently offer a Patient Assistance Program to help offset some of the patients' financial responsibility."

Dr. Rafaeli continued, "Furthermore, our reimbursement support team coordinates patient insurance coverage with the various payers, before that patient even steps foot in the clinic and continues through the patient's completion of the therapy. STRATA's DTC advertising program drives patient traffic to our partner physician clinics. We help schedule new patients' visits to make the process as simple as possible for both patient and provider. STRATA has a proven record of being able to offer 90% of DTC patients an introduction to XTRAC locations prescribing a reimbursable solution within 10 miles of their home."

### **About STRATA Skin Sciences, Inc.**

([www.strataskin.com](http://www.strataskin.com))

STRATA Skin Sciences is a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC<sup>®</sup> excimer laser and VTRAC<sup>®</sup> lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions; and the STRATAPEN<sup>®</sup> MicroSystem, marketed specifically for the intended use of micropigmentation.

---

The Company's proprietary XTRAC<sup>®</sup> excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases, which impact over 35 million patients in the United States alone. The technology is covered by multiple patents, including exclusive rights for patents for the delivery of treatments to vitiligo patients.

STRATA's unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

The XTRAC business has used this proven DTC model to grow its domestic dermatology partner network to over 740 clinics, with a worldwide installed base of over 2,000 devices. The Company is able to offer 90% of DTC patients an introduction to physicians prescribing a reimbursable solution, using XTRAC, within a 10 mile radius of their house. The Company is a leader in dermatology in-clinic business generation for its partners.

### **Safe Harbor**

*This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, including the Company's ability to sell products to U.S. Dermatology clinics, generate the anticipated revenue stream, the Company's ability to generate sufficient cash flow to fund the Company's ongoing operations beginning at any time in the future, the Company's ability to license or acquire new products, the public's reaction to the Company's new advertisements and marketing campaign, access to capital markets, and the Company's ability to build a leading franchise in dermatology and aesthetics, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at [www.sec.gov](http://www.sec.gov) and [www.strataskin.com](http://www.strataskin.com).*

### **Investor Contacts:**

Matthew C. Hill, Chief Financial Officer  
STRATA Skin Sciences, Inc.  
215-619-3200  
[ir@strataskin.com](mailto:ir@strataskin.com)

Jeremy Feffer, Managing Director  
LifeSci Advisors, LLC  
212-915-2568  
[jeremy@lifesciadvisors.com](mailto:jeremy@lifesciadvisors.com)

---

---